The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...
Stocktwits on MSN
The 2025 weight-loss drug gold rush: How Eli Lilly pulled ahead, Novo hit a snag — and a swarm of biotech underdogs are closing in
Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback